Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae

Clin Mol Hepatol. 2022;28(2):196-206. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0371

View: 6656 Download: 219 Web of Science: 19 Crossref: 19

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients

Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(2):183-195. Published online November 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0301

View: 6534 Download: 220 Web of Science: 6 Crossref: 7

Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods

Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park

Clin Mol Hepatol. 2022;28(1):105-116. Published online October 15, 2021

DOI: https://doi.org/10.3350/cmh.2021.0174

View: 8183 Download: 226 Web of Science: 9 Crossref: 9

Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes

Hydar El Jamaly, Guy D Eslick, Martin Weltman

Clin Mol Hepatol. 2022;28(1):52-66. Published online September 17, 2021

DOI: https://doi.org/10.3350/cmh.2021.0205

View: 8055 Download: 241 Web of Science: 14 Crossref: 17

Editorial

Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment

Ja-Young Kwon

Clin Mol Hepatol. 2022;28(1):50-51. Published online November 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0359

View: 4600 Download: 107

Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?

Seung Mi Lee, Won Kim

Clin Mol Hepatol. 2022;28(1):47-49. Published online November 30, 2021

DOI: https://doi.org/10.3350/cmh.2021.0338

View: 4697 Download: 117 Web of Science: 4 Crossref: 4

Review

Recent advances in nonalcoholic fatty liver disease metabolomics

Hwi Young Kim

Clin Mol Hepatol. 2021;27(4):553-559. Published online June 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0127

View: 11495 Download: 514 Web of Science: 47 Crossref: 48

Original Article

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed

Clin Mol Hepatol. 2021;27(3):486-498. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2020.0162

View: 6866 Download: 269 Web of Science: 23 Crossref: 24

Editorial

An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Dae Won Jun

Clin Mol Hepatol. 2021;27(3):446-447. Published online May 21, 2021

DOI: https://doi.org/10.3350/cmh.2021.0133

View: 5046 Download: 160 Web of Science: 5 Crossref: 6

Guideline

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0178

View: 21432 Download: 1,257 Web of Science: 171 Crossref: 178

Original Article

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 8125 Download: 240 Web of Science: 17 Crossref: 17

Review

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee, On behalf of Korean NAFLD Study Group

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0067

View: 9821 Download: 445 Web of Science: 69 Crossref: 71

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0239

View: 9506 Download: 374 Web of Science: 28 Crossref: 33

Original Article

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk

Clin Mol Hepatol. 2021;27(1):110-124. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0125

View: 11042 Download: 485 Web of Science: 79 Crossref: 80

Editorial

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 5562 Download: 170 Web of Science: 1 Crossref: 1

Review

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

Gwyneth Soon, Aileen Wee

Clin Mol Hepatol. 2021;27(1):44-57. Published online November 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0181

View: 14111 Download: 378 Web of Science: 39 Crossref: 41

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Erica Jennison, Christopher D. Byrne

Clin Mol Hepatol. 2021;27(1):22-43. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0129

View: 10818 Download: 446 Web of Science: 55 Crossref: 60

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0202

View: 7374 Download: 202 Web of Science: 27 Crossref: 26

Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease

Sen Han, Ting Zhang, Praveen Kusumanchi, Nazmul Huda, Yanchao Jiang, Zhihong Yang, Suthat Liangpunsakul

Clin Mol Hepatol. 2020;26(4):705-714. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0166

View: 5395 Download: 107 Web of Science: 13 Crossref: 12

Letter to the Editor

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0264

View: 4113 Download: 71 Web of Science: 2 Crossref: 2

Review

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0136

View: 9550 Download: 295 Web of Science: 44 Crossref: 43

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 11016 Download: 498 Web of Science: 44 Crossref: 46

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

Theresa J. Hydes, Sujan Ravi, Rohit Loomba, Meagan E. Gray

Clin Mol Hepatol. 2020;26(4):383-400. Published online July 17, 2020

DOI: https://doi.org/10.3350/cmh.2020.0067

View: 11714 Download: 534 Web of Science: 56 Crossref: 58

Letter to the Editor

Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease

Jung Hwan Yu

Clin Mol Hepatol. 2020;26(2):240-241. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0048

View: 4538 Download: 52 Web of Science: 1 Crossref: 1

Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?

Hyuk Soo Eun

Clin Mol Hepatol. 2020;26(2):236-237. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0040

View: 4250 Download: 49

Original Article

Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease

Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky

Clin Mol Hepatol. 2020;26(2):216-226. Published online December 5, 2019

DOI: https://doi.org/10.3350/cmh.2019.0074

View: 7609 Download: 145 Web of Science: 17 Crossref: 16

Editorial

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?

Soung Won Jeong

Clin Mol Hepatol. 2020;26(2):185-186. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0046

View: 5132 Download: 92 Web of Science: 2 Crossref: 2

Review

Application of transient elastography in nonalcoholic fatty liver disease

Xinrong Zhang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2020;26(2):128-141. Published online November 8, 2019

DOI: https://doi.org/10.3350/cmh.2019.0001n

View: 16204 Download: 578 Web of Science: 72 Crossref: 79

Letter to the Editor

Carnitine palmitoyl transferase 1A deficiency in an adult with recurrent severe steatohepatitis aggravated by high pathologic or physiologic demands: A roller-coaster for internists

Prasit Phowthongkum, Kanya Suphapeetiporn, Vorasuk Shotelersuk

Clin Mol Hepatol. 2019;25(4):412-416. Published online June 24, 2019

DOI: https://doi.org/10.3350/cmh.2018.0114

View: 5987 Download: 146 Web of Science: 6 Crossref: 4

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease

Dimitrios Patoulias, Konstantinos Imprialos, Konstantinos Stavropoulos, Michael Doumas

Clin Mol Hepatol. 2019;25(3):331-332. Published online May 30, 2019

DOI: https://doi.org/10.3350/cmh.2019.0034

View: 4872 Download: 59 Crossref: 1

Viewed By 6180	MAFLD: How is it different from NAFLD?
Viewed By 5274	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4999	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4168	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3941	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 155	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis